Cargando…

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients

PURPOSE: We presented retrospective analysis of up to five polymorphisms in TS, MTHFR and ERCC1 genes as molecular predictive markers for homogeneous Caucasian, non-squamous NSCLC patients treated with pemetrexed and platinum front-line chemotherapy. METHODS: The following polymorphisms in DNA isola...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krawczyk, Paweł, Kucharczyk, Tomasz, Kowalski, Dariusz M., Powrózek, Tomasz, Ramlau, Rodryg, Kalinka-Warzocha, Ewa, Winiarczyk, Kinga, Knetki-Wróblewska, Magdalena, Wojas-Krawczyk, Kamila, Kałakucka, Katarzyna, Dyszkiewicz, Wojciech, Krzakowski, Maciej, Milanowski, Janusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article – Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4228108/ https://www.ncbi.nlm.nih.gov/pubmed/25028118 http://dx.doi.org/10.1007/s00432-014-1756-6

Ejemplares similares

The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients
por: Kucharczyk, Tomasz, et al.
Publicado: (2015)

The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma
por: Krawczyk, Paweł, et al.
Publicado: (2013)

Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study
por: Krawczyk, Paweł, et al.
Publicado: (2014)

The analysis of ALK gene rearrangement by fluorescence in situ hybridization in non-small cell lung cancer patients
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2013)

Septin 9 promoter region methylation in free circulating DNA—potential role in noninvasive diagnosis of lung cancer: preliminary report
por: Powrózek, Tomasz, et al.
Publicado: (2014)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
por: Bożyk, Aleksandra, et al.
Publicado: (2021)

Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
por: Krawczyk, Paweł, et al.
Publicado: (2012)

The Application of Real-Time PCR Technique to Detect Rare Cell Clones with Primary T790M Substitution of EGFR Gene in Metastases of Non-small Cell Lung Cancer to Central Nervous System in Chemotherapy Naive Patients
por: Powrózek, Tomasz, et al.
Publicado: (2014)

Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience
por: Chmielewska, Izabela, et al.
Publicado: (2021)

Beyond PD-L1 Markers for Lung Cancer Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2019)

Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine
por: Mlak, Radosław, et al.
Publicado: (2018)

Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
por: Krawczyk, Paweł, et al.
Publicado: (2015)

Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
por: Grenda, Anna, et al.
Publicado: (2021)

Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2016)

Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2021)

Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer
por: Nicoś, Marcin, et al.
Publicado: (2014)

Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2023)

Double Guard Efficiency and Safety—Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients
por: Kalinka, Ewa, et al.
Publicado: (2023)

Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
por: Krawczyk, Paweł, et al.
Publicado: (2017)

Evaluation of miR-506 and miR-4316 expression in early and non-invasive diagnosis of colorectal cancer
por: Krawczyk, Paweł, et al.
Publicado: (2017)

Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2020)

Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system
por: KRAWCZYK, PAWEŁ, et al.
Publicado: (2013)

EGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short report
por: Kamila, Wojas-Krawczyk, et al.
Publicado: (2013)

Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
por: Nicoś, Marcin, et al.
Publicado: (2019)

HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery
por: Grenda, Anna, et al.
Publicado: (2020)

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Clinical Application Perspectives of Lung Cancers 3D Tumor Microenvironment Models for In Vitro Cultures
por: Wieleba, Irena, et al.
Publicado: (2022)

Tumor Microenvironment—A Short Review of Cellular and Interaction Diversity
por: Bożyk, Aleksandra, et al.
Publicado: (2022)

New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary
por: Krawczyk, Paweł, et al.
Publicado: (2022)

Viral Infection and Lung Cancer Immunotherapy
por: Kalinka, Ewa, et al.
Publicado: (2021)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

RET Proto-Oncogene—Not Such an Obvious Starting Point in Cancer Therapy
por: Kucharczyk, Tomasz, et al.
Publicado: (2022)

Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of The Art and Future Directions
por: Stencel, Katarzyna, et al.
Publicado: (2021)

Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients
por: Frąk, Małgorzata, et al.
Publicado: (2021)

The impact of ACE gene polymorphism on the incidence and phenotype of sarcoidosis in rural and urban settings
por: Kieszko, Robert, et al.
Publicado: (2015)

The influence of different culture microenvironments on the generation of dendritic cells from non-small-cell lung cancer patients
por: Krawczyk, Paweł, et al.
Publicado: (2007)

Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland
por: Kowalski, Dariusz M., et al.
Publicado: (2012)

Imperfect Predictors for Lung Cancer Immunotherapy—A Field for Further Research
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mlbdqdc0t7nk29tp2k10c3rbq7